ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT05748834

Public ClinicalTrials.gov record NCT05748834. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Single Arm Trial With a Safety Lead-in of Tucatinib in Combination With Doxil for the Treatment of HER2+ Metastatic Breast Cancer

Study identification

NCT ID
NCT05748834
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
SCRI Development Innovations, LLC
Other
Enrollment
36 participants

Conditions and interventions

Conditions

Interventions

  • Doxil Drug
  • Tucatinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 23, 2023
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027
Last update posted
Mar 19, 2026

2023 – 2027

United States locations

U.S. sites
8
U.S. states
5
U.S. cities
7
Facility City State ZIP Site status
Maryland Oncology Hematology Columbia Maryland 21044 Recruiting
Alliance Cancer Specialists Bensalem Pennsylvania 19020 Recruiting
SCRI Oncology Partners Nashville Tennessee 37203 Recruiting
Tennessee Oncology Nashville Tennessee 37203 Active, not recruiting
Texas Oncology- DFW Dallas Texas 75246 Recruiting
Texas Oncology- San Antonio San Antonio Texas 78240 Recruiting
Virginia Oncology Associates Norfolk Virginia 23502 Recruiting
Blue Ridge Cancer Care (Oncology & Hematology Assoc of SW Virginia, Inc) Salem Virginia 24153 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05748834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 19, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05748834 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →